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Abstract 25 
The tremendous diversity in microbial species that colonise the mucosal surfaces of the 26 
human body is only now beginning to be fully appreciated. Distinguishing between the 27 
behaviour of commensal microbes and harmful pathogens that reside at mucosal sites in 28 
the body is a complex, and exquisitely fine-tuned process central to mucosal health. The 29 
fungal pathobiont Candida albicans is frequently isolated from mucosal surfaces with an 30 
asymptomatic carriage rate of approximately 60% in the human population. While normally 31 
a benign member of the microbiota, overgrowth of C. albicans often results in localised 32 
mucosal infection causing morbidity in otherwise healthy individuals, and invasive infection 33 
that often causes death in the absence of effective immune defence. C. albicans triggers 34 
numerous innate immune responses at mucosal surfaces, and detection of C. albicans 35 
hyphae in particular, stimulates the production of antimicrobial peptides, danger-associated 36 
molecular patterns and cytokines that function to reduce fungal burdens during infection. 37 
This review will summarise our current understanding of innate immune responses to C. 38 
albicans at mucosal surfaces. 39 
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1. Introduction 49 
In the past, mucosal surfaces were often considered to be merely a static barrier 50 
between the body and the external environment. However, recent research has now 51 
redefined mucosal barriers and the epithelial cells that comprise them as highly complex 52 
and dynamic structures capable of initiating and modulating several crucial host responses 53 
required to maintain tissue homeostasis during health and disease. The mucosal surfaces of 54 
the human body provide a varied and challenging niche for bacteria, fungi and viruses. The 55 
incredible diversity within the microbial communities that colonise the host mucosa makes 56 
differentiating between harmless commensalism and pathogenic behaviour difficult, 57 
particularly in the context of pathobionts, which can remain passive for extended periods of 58 
time before displaying pathogenic behaviour that is damaging to the host.  59 
Fungi, particularly Candida species, are frequently isolated from the skin [1] and the 60 
mucosal surfaces of the body [2]. While C. albicans is often regarded as the most pathogenic 61 
of the Candida species, C. tropicalis, C. glabrata, C. parapsilosis, C. krusei and others 62 
contribute significantly to morbidity and mortality. Indeed, the recent emergence of fungal 63 
pathogens such as C. auris [3] highlight the prominence of Candida species and the 64 
unrelenting threat they pose to human health. 65 
The morphological plasticity of C. albicans is a central virulence trait that facilitates 66 
mucosal pathogenesis. Overgrowth of C. albicans hyphae at mucosal surfaces occurs when 67 
host defences are diminished, resulting in localised mucosal infection. C. albicans infections 68 
of the oral cavity [2] present as creamy-white fungal plaques on the oral mucosa 69 
(pseudomembranous candidiasis), painful reddened lesions on the tongue (erythematous 70 
candidiasis) and smooth or nodular lesions on any mucosal surface within the mouth 71 
(chronic hyperplastic candidiasis). Growth of C. albicans on mucosal surfaces and abiotic 72 
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substrates results in the formation of biofilms, which are of increasing concern in medical 73 
settings [4, 5]. Regular contact between Candida biofilm and the hard palate of the oral 74 
cavity can result in Candida-associated denture stomatitis, and lifestyle choices (particularly 75 
smoking) can result in median rhomboid glossitis of the tongue. Candida species are 76 
frequently isolated from the gastrointestinal tract [6], which is widely regarded as the 77 
primary tissue from which the majority of systemic infections are acquired (usually following 78 
surgery or major abdominal trauma). Thus, mucosal colonisation by Candida species (and C. 79 
albicans in particular), is a major risk factor for potential life-threatening candidaemia. 80 
The skin [1, 7] and mucosal surfaces of the body have evolved a number of incredibly 81 
sensitive and discerning mechanisms that allow appropriate immune defence to be initiated 82 
and controlled in response to changes in microbial behaviour. This article will review our 83 
current understanding of innate defences against C. albicans at mucosal surfaces.  84 
 85 
2. The role of the mycobiome in relation to anti-fungal immunity 86 
With the recent advances made in high-throughput sequencing technologies, 87 
researchers are now able to accurately characterise the complex microbial communities 88 
that develop within human habitats. The astonishing extent and complexity of these 89 
communities that has been revealed in these studies has suggested a level of importance in 90 
human health and disease that is only now beginning to be understood, with the 91 
“superorganism” or “holobiont” hypotheses being proposed [8]. However, despite the 92 
advances being made in this field, attention has largely focussed on the bacterial 93 
components of these rich microbial communities.  94 
To date, the fungal communities, or mycobiome, have yet to be systematically 95 
investigated in the same way. There are several reasons for this.  First, despite their 96 
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considerable biomass, fungi account for a relatively small percentage of the genes within 97 
the microbiome as compared to bacteria and archaea [9, 10]. Second, isolation of high-98 
quality nucleic acids in sufficient quantities from fungal cells in a microbial community is 99 
challenging due to the complex cell wall structures that fungal cells possess, and requires a 100 
combination of enzymatic, chemical and mechanical lysis steps that vary with different fungi 101 
[11]. Finally, discrimination between the different fungal taxa is dependent on the 102 
databases and reference genome catalogues that are available. These databases are 103 
currently either incomplete or, in the case of reference genome catalogues, not available at 104 
present [12, 13]. However, the data that is available points to a critical role for the 105 
mycobiome and fungal components within it, in human health and disease [6, 14-16].  106 
Indeed, microbiome analysis of HIV-positive and -negative individuals reveal long-107 
term shifts in the mycobiome but not the bacteriome [17]. While some taxa, such as 108 
Candida and Penicillium appeared in all individuals, HIV-negative individuals were 109 
specifically associated with Pichia, Cladosporium and Fusarium species, while HIV-positive 110 
individuals showed the presence of Alternaria, Epicoccum and Trichosporon. Moreover, 111 
species common to both cohorts, including Candida, show differences in their relative 112 
abundance. These changes arise from complex interactions between individual taxa of the 113 
mycobiome and demonstrate that the Pichia spp associated with a healthy mycobiota 114 
produce factors that suppress the growth of pathogenic fungi such as Candida spp that 115 
show greater prevalence in HIV-positive individuals [17]. Thus, the loss of Pichia in HIV-116 
positive individuals may in part, explain the prevalence of oral candidiasis associated with 117 
HIV-positive status, as a natural inhibitor of Candida is lost. 118 
In general, changes in the mycobiota are associated with modulation of immune 119 
responses and disease progression [6, 18], as well as maintenance of microbial population 120 
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architecture and host metabolic function [19]. Furthermore, components of the mycobiota 121 
interact with bacteria to impact on disease [15]. For example, the microbiota of Crohn’s 122 
disease patients contains an abundance of Candida tropicalis compared with healthy 123 
controls, and positively correlates with the production of anti-Saccharomyces cerevisiae 124 
antibodies; a diagnostic biomarker of Crohn’s disease [15]. Furthermore, both Serratia 125 
marcesens and Escherichia coli are elevated in Crohn’s patients, while “beneficial” bacteria 126 
(e.g. Faecalibacterium prausnitzii) show a significant decrease in their abundance.  127 
Strikingly, the abundance of S. marcesens, E. coli and C. tropicalis in patients with 128 
Crohn’s disease positively correlate with one another; the biomass and thickness of these 129 
triple species biofilms are significantly greater than those of single and double species 130 
biofilms, with enrichment in the number of C. tropicalis hyphae that bind directly to both 131 
bacteria through fimbrial connections [15]. Thus, specific interkingdom microbial 132 
interactions may be key determinants in Crohn’s disease. Although there is mounting 133 
evidence that links changes in the micro/mycobiota with disease, there remains much to 134 
understand regarding the complex interactions between the mycobiota, the remaining 135 
microbiota, and the host. In order for C. albicans to cause disease at a mucosal surface, it 136 
must first interact with epithelial cells. The interactions that occur between C. albicans and 137 
epithelial cells are described below. 138 
 139 
3. Interaction of Candida albicans with the host mucosa 140 
3.1 Adhesion to epithelial cells 141 
Attachment of C. albicans yeast and hyphae to epithelial cells is a prerequisite for 142 
colonisation and accordingly, a risk factor for the development of mucosal infection. 143 
Attachment of C. albicans to mucosal sites of the body can be mediated either directly or 144 
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indirectly through association with bacterial and fungal components of the microbiota. 145 
While C. albicans yeast cells are capable of interacting with and adhering to the host mucosa 146 
[20], the switch to hyphal growth invokes extensive transcriptional reprogramming of the 147 
fungus [21, 22], leading to changes in the composition of the fungal cell wall [23] that enable 148 
a more robust interaction with the epithelial surface to be established and maintained [24]. 149 
Two key C. albicans hypha-associated adhesins in this process are Als3p and Hwp1p, which 150 
mediate direct attachment to epithelial cells.  151 
The Agglutinin-Like Sequence (Als) family of C. albicans adhesins contains eight 152 
members (Als1-7p and Als9p) which are GPI-linked to β-1-6 glucans in the fungal cell wall. 153 
Each member of the Als family contains an N-terminal substrate-binding domain, a highly 154 
variable central serine/threonine-rich domain comprised of numerous 36 amino acid 155 
tandem repeat sequences, and a C-terminal domain containing the GPI anchor [25]. The Als 156 
proteins of C. albicans exhibit a complex pattern of morphology-dependent and -157 
independent expression that varies between individual clinical specimens, in vivo disease 158 
models, and fungal culture conditions in vitro [25, 26].  159 
Als3p is strongly upregulated during epithelial infection [27], and disruption of ALS3 160 
reduces epithelial adhesion in vitro. Similarly, an als2Δ/PMAL2-ALS2 mutant (where the one 161 
remaining wild type copy of ALS2 in a heterozygous ALS2 knockout is placed under the 162 
control of a regulatable promoter) also exhibited reduced epithelial adhesion [28]. In 163 
contrast, deletion of C. albicans ALS5, ALS6 or ALS7 increases fungal adhesion to the 164 
epithelium [29], indicating that the Als proteins have varied roles in mediating adherence to 165 
host mucosa. However, despite these findings, conflicting observations have been made 166 
regarding the precise role of ALS1, ALS2 and ALS4-6 in epithelial attachment [30-32]. 167 
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The structural similarity that exists between specific C. albicans proteins and those of 168 
the host can in some instances be exploited to confer an advantage to the fungus. Hyphal 169 
Wall Protein 1 (Hwp1p) is a hypha-associated adhesin that is strongly expressed during 170 
colonisation and infection of the oral mucosa [27, 33]. The amino acid sequence of the 171 
Hwp1p N-terminal domain closely resembles that of natural substrates for mammalian 172 
transglutaminase enzymes [34]. By mimicking a natural host substrate, C. albicans exploits 173 
host transglutaminase activity, which covalently couples the N-terminal domain of Hwp1p to 174 
the epithelial surface [35]. Hwp1p has a greater affinity for terminally differentiated 175 
epithelial cells that display SPR3 and keratin 13 when compared with less differentiated cells 176 
[36], and deletion of HWP1 results in reduced epithelial adhesion and virulence in a murine 177 
model of oropharyngeal candidiasis (OPC) [35, 37]. However, while the role of Hwp1p in 178 
mucosal infection is clearly established, it plays a minimal role in systemic infection and is 179 
therefore habitat specific [38]. 180 
C. albicans Int1p is an adhesin with structural similarity to human leukocyte integrin. 181 
Int1p is required for hyphal growth, intestinal colonisation in mice and virulence in vivo [39]. 182 
Heterologous expression of INT1 in the non-adherent yeast Saccharomyces cerevisiae 183 
confers adhesion to epithelial cells [39, 40], confirming the role of Int1p as a primary 184 
adhesin. Phenotypes associated with INT1 expression are complex and dose dependent, as 185 
reintegration of a single copy of wild type INT1 into an int1Δ/Δ null mutant background 186 
restores hyphal growth but not epithelial attachment [39].  187 
While only a handful of C. albicans proteins have been identified that mediate 188 
epithelial adhesion directly, numerous factors have been identified that exert an indirect 189 
influence on epithelial attachment. Collectively, these factors affect multiple pathways and 190 
processes including the expression and appropriate presentation of adhesins on the fungal 191 
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cell wall, and the activation of hypha-associated transcriptional circuitry required to induce 192 
the expression of morphology-dependent genes required for enhanced epithelial 193 
interaction. The factors that indirectly influence the interaction of C. albicans with host 194 
mucosa are presented in Table 1.  195 
 196 
Table 1. Factors that indirectly influence attachment of C. albicans to epithelial cells. 197 
Gene Function Epithelial 
Adhesion of 
Null Mutant 
Epithelial 
Cell Type 
Reference 
BIG1 Endoplasmic reticulum 
protein 
Decreased HeLa [41] 
BST1 Inositol deacylase Decreased Caco-2 
KB 
[42] 
CDC10 Septin protein Decreased HeLa [43] 
CFL1 Ferric reductase Decreased HeLa [44] 
CSF4 Putative glycosidase Decreased FaDu [45] 
EAP1 GPI-anchored cell wall 
protein 
Decreased HEK293 [46] 
EFG1 Transcription factor Decreased Caco-2 [47] 
IFF4 GPI-anchored cell wall 
protein 
Overexpression 
increases 
adherence 
FaDu [48] 
IPT1 Sphingolipid biosynthesis Decreased Gingival [49] 
IRS4 Cell wall integrity Decreased HT-29 
HeLa 
FaDu 
[50] 
KRE5 Glucosyl transferase Decreased HeLa [51] 
MNT1 Mannosyl transferase Decreased Buccal [52] 
MNT2 Mannosyl transferase Decreased Buccal [53] 
MP65 Putative β-glucanase 
enzyme 
Decreased Buccal 
Caco-2 
[54] 
NOT5 Putative transcriptional 
complex component 
Decreased Buccal [55] 
PDE2 Phosphodiesterase Decreased Buccal [56] 
PGA1 Putative GPI-anchored 
protein 
Decreased HT-29 [57] 
PHR1 β-(1, 3)-
glucanosyltransferase 
Decreased TR146 
Caco-2 
[58] 
PMT1 Protein 
mannosyltransferase 
Decreased Caco-2 
 
[59] 
PRA1 Zinc sequestration Decreased HEK293 [60] 
SAP1 Aspartic proteinase Decreased Buccal [61] 
SAP2 Aspartic proteinase Decreased Buccal [61] 
SAP3 Aspartic proteinase Decreased Buccal [61] 
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SAP4-6 Aspartic proteinases Increased Buccal [61] 
SAP9 Aspartic proteinase Increased Buccal [62] 
SAP10 Aspartic proteinase Decreased Buccal [62] 
SET1 Methyl transferase Decreased FaDu 
HT-29 
[63] 
SUN41 Putative glycosidase Decreased Caco-2 [64] 
TUP1 Transcriptional 
corepressor 
Decreased SCC15 [65] 
VAC1 Putative vesicle transport 
protein 
Decreased SK-LMS-1 [66] 
 198 
3.2 Epithelial recognition of C. albicans 199 
Physical recognition of C. albicans by host mucosa is achieved through the 200 
interaction of epithelial pattern recognition receptors (PRRs) with pathogen-associated 201 
molecular patterns (PAMPs). Fungal PAMPs include cell wall proteins which contain 202 
conserved structural motifs that are projected from the cell wall into the extracellular 203 
environment, and intracellular molecules such as nucleic acids. Toll-like receptors (TLRs), C-204 
type lectin receptors (CLRs) and nucleotide-binding domain leucine-rich receptors (NLRs) 205 
comprise the three main families of PRR. A successful PRR-PAMP interaction activates 206 
epithelial signalling pathways that contribute to innate defence against fungal infection. 207 
While the involvement of PRRs in anti-fungal responses is well documented for myeloid cells 208 
[67] (and see sections 7 and 8), relatively little is known about the PRRs involved during 209 
epithelial recognition of C. albicans. 210 
The epithelial ephrin type-A receptor 2 (EphA2) is a recently identified non-classical 211 
PRR that binds to exposed β-glucans of C. albicans yeast and hyphae [68]. β-glucan-induced 212 
phosphorylation of EphA2 is dependent upon fungal burden, and a yeast locked 213 
(efg1/cph1Δ/Δ) C. albicans mutant stimulates EphA2 phosphorylation within 15 min, 214 
indicating that epithelial recognition of fungus through EphA2 is morphology-independent. 215 
Activation of EphA2 results in phosphorylation of MEK1/2 and p38 (leading to downstream 216 
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activation of c-Fos), phosphorylation of signal transducer and activator of transcription 3 217 
(Stat3), and secretion of human beta defensin-2, chemokine (C-C motif) ligand 20 (CCL20), 218 
interleukin (IL)-1α, IL-1β and IL-8 [68]. Thus, epithelial recognition of C. albicans β-glucan via 219 
EphA2 results in antifungal and pro-inflammatory responses. The importance of EphA2-220 
mediated innate recognition of C. albicans in vivo is highlighted by the observation that 221 
immune competent EphA2-/- knockout mice have higher fungal burdens in the oral cavity 222 
when compared to wild type mice [68]. 223 
All TLRs (except TLR7) are expressed by reconstituted human oral epithelium, and all 224 
except TLR5 and TLR7 are detectable in buccal epithelial cells from healthy donors [69]. 225 
Epithelial TLR4 in particular, plays a direct role in mucosal defence against C. albicans 226 
infection, a process that is dependent upon an intimate relationship with neutrophils. While 227 
infection of oral epithelial cells with C. albicans in vitro results in cellular damage and a 228 
robust pro-inflammatory response, expression of TLR4 remains unchanged compared to 229 
uninfected cells [69]. However, in the presence of polymorphonuclear leukocytes, epithelial 230 
cells secrete immune modulators that stimulate a robust PMN-mediated upregulation of 231 
epithelial TLR4, concomitant with a reduction in epithelial damage and protection against 232 
fungal invasion [69]. 233 
 234 
3.3 Invasion of mucosal barriers 235 
Invasion of mucosal barriers by C. albicans is commensurate with localised infection. 236 
While yeast and hyphal morphologies of C. albicans are capable of adhering to the host 237 
mucosa, it is predominantly the hyphal form of the fungus that invades into the epithelial 238 
surface. C. albicans uses two temporally and mechanistically distinct mechanisms of 239 
invasion that together enable the fungus to access the superficial and underlying epithelial 240 
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tissues. These mechanisms are receptor-mediated induced endocytosis and active 241 
penetration. 242 
 243 
3.4 Receptor-induced endocytosis 244 
Once attached to the epithelial surface, the hyphae of C. albicans invade mucosal 245 
barriers by initiating a dynamic and complex host-driven process called receptor-induced 246 
endocytosis (RIE) [70, 71]. Indeed, the invading fungus remains completely passive during 247 
RIE, as hyphae that are rendered metabolically inviable by thimerosal treatment are still 248 
endocytosed by epithelial cells [71]. Endocytosis of C. albicans hyphae is triggered by 249 
epithelial recognition of fungal invasins expressed on the hypha cell wall, and occurs within 250 
4 h of initial contact with epithelial cells [72].  251 
 While several host receptors are implicated in the process of fungal endocytosis, 252 
only two fungal invasins have been identified as triggers of internalisation: the adhesin 253 
Als3p, and Ssa1p (a member of the heat shock protein (HSP) 70 family of proteins) 254 
expressed on the C. albicans cell wall [73, 74]. Disruption of either ALS3 or SSA1 result in 255 
reduced invasion of epithelial cells and attenuated virulence in a murine model of OPC [73-256 
75], with Als3p in particular playing a dominant role in this process. Als3p and Ssa1p are 257 
recognised by the epithelial receptor E-cadherin [73, 74], an interaction that stimulates a 258 
dynamic, hypha-induced reorganisation of epithelial clathrin, dynamin and cortactin that 259 
culminates in the formation of pseudopods that surround the fungus and facilitate 260 
internalisation [76]. Interestingly, inhibition of E-cadherin receptor activity results in a 261 
partial, but not complete block of fungal endocytosis [77], suggesting the involvement of 262 
additional host epithelial receptors and/or pathways in fungal internalisation. Indeed, 263 
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remodelling of the actin cytoskeleton in rabbit corneal epithelial cells is dependent on the 264 
small GTPases Cdc42, Rac1, RhoA and the tight junction protein ZO-1 [78].  265 
Recognition of C. albicans Als3p and Ssa1p can also occur through interaction with a 266 
heterodimeric receptor complex comprised of the epidermal growth factor receptor 267 
(EGFR/HER1) and HER2 expressed on epithelial cells [77]. Latex beads coated with a 268 
recombinant N-terminal region of Als3p or recombinant Ssa1p are rapidly endocytosed by 269 
epithelial cells in vitro [73, 74], identifying both proteins as ligands that stimulate epithelial 270 
internalisation. During infection of oral epithelial cells in vitro, C. albicans activates the 271 
platelet-derived growth factor BB (PDGF BB) and neural precursor-cell-expressed 272 
developmentally down-regulated protein 9 (NEDD9) pathways in a cadherin-independent 273 
manner [79]. In contrast, analysis of samples obtained during a clinical study of vaginal 274 
candidiasis revealed that the PDGF BB, but not NEDD9 pathway is activated in response to 275 
infection [79], highlighting the tissue specific nature of epithelial responses to the fungus. 276 
The aryl hydrocarbon receptor (AhR) is a cytoplasmic ligand-activated transcription 277 
factor that plays a central role in EGFR-mediated endocytosis of C. albicans in vitro and in 278 
vivo [80]. Infection of oral epithelial cells with C. albicans activates the AhR, which in turn 279 
leads to phosphorylation of Src family kinases, culminating in EGFR activation and fungal 280 
endocytosis. Inhibition of the AhR in immune-competent and immune-suppressed mice was 281 
found to reduce the severity of OPC [80], highlighting the contribution of AhR signalling to 282 
disease pathology. Given the intracellular location of the AhR, the mechanism of C. albicans-283 
mediated receptor activation is likely to be indirect. However, the specific ligand that is 284 
induced by C. albicans to activate the AhR has yet to be identified. Small interfering RNA 285 
(siRNA)-mediated depletion of EphA2 also reduces RIE of C. albicans [68]. EphA2 knockdown 286 
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and chemical inhibition of receptor activity reduce EGFR phosphorylation, suggesting that 287 
EphA2 and EGFR function in the same endocytosis pathway [68]. 288 
Knockout studies investigating the role of the transcription factor Rim101p have 289 
provided further insight into the fungal proteins required to induce the uptake of C. albicans 290 
by epithelial cells. A C. albicans rim101∆/∆ mutant was unable to efficiently initiate RIE by 291 
oral epithelial cells [81]. Notably, however, overexpression of Cht2p, Pga7p or Zrt1p in a 292 
rim101∆/∆ mutant background restored the ability of C. albicans to trigger RIE efficiently, 293 
implicating these proteins in the process of epithelial internalisation. Despite the great 294 
advances made in our understanding of RIE, the molecular signalling events that drive this 295 
epithelial response are yet to be characterised in full and the extent of receptor and 296 
pathway redundancy between mechanisms remains to be explored in detail. The C. albicans 297 
factors involved in the processes of epithelial adhesion and RIE are presented in Figure 1A. 298 
 299 
3.5 Active penetration of mucosal surfaces 300 
Mucosal surfaces vary in their structure and cellular composition depending on 301 
location within the body. The stratified mucosa of the oral and vaginal lumen comprise 302 
several layers of epithelial cells, the outermost of which are terminally differentiated, 303 
whereas the epithelium that lines the gastrointestinal (GI) tract is composed of a single 304 
(non-stratified) layer of cells. Terminally differentiated epithelial cells are non-proliferative 305 
and considered less capable of supporting RIE. In order to invade a mucosal barrier that 306 
does not readily internalise hyphae, C. albicans uses the process of active penetration. 307 
Unlike RIE, where the fungus remains passive during uptake [71], active penetration 308 
of host mucosa by C. albicans hyphae relies upon physical attributes of the fungus including 309 
turgor pressure, physical advancement of the hyphal tip, and secretion of hydrolytic 310 
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enzymes that facilitate fungal invasion through or between epithelial cells. Paradoxically, 311 
while only a single cell thick, the GI epithelium does not support fungal invasion by RIE, but 312 
by active penetration only, highlighting specific differences in epithelial responses to C. 313 
albicans. The mucosal barrier of the GI tract is coated with a layer of mucus. C. albicans 314 
hyphae secrete the aspartic proteinase Sap2p that degrades gastroinestinal mucins [82] and 315 
Sap5p that degrades E-cadherin [83], weakening the adherens junctions between epithelial 316 
cells, which may facilitate the translocation of fungus across the gut. Despite these 317 
contributions however, our understanding of the fungal proteins required for the process of 318 
active penetration remains incomplete.  319 
Surprisingly, Als3p is not essential for active penetration as an als3∆/∆ null mutant 320 
can still invade epithelial cells that are unable to endocytose hyphae [75]. However, Als3p 321 
may nevertheless provide points of anchorage on the mucosal surface which enable hyphal 322 
pressure upon the epithelial barrier to be sustained. Active penetration of C. albicans 323 
hyphae through mucosal barriers is delayed in onset compared with RIE and is also 324 
mechanistically distinct, as blocking the polymerisation of epithelial actin does not prevent 325 
the mucosa from being breached [75, 84]. In vivo, it is likely that a combination of active 326 
penetration and RIE are required for full invasion of stratified epithelial barriers. Active 327 
penetration across the outermost (terminally differentiated) epithelial layers is thought to 328 
occur first, and this is followed by RIE, when the invading fungus reaches the underlying 329 
(non-terminally differentiated) epithelial cells. 330 
 331 
4. Candidalysin: epithelial damage and innate immunity  332 
One of the hallmarks of C. albicans infection of mucosal surfaces is damage to the 333 
superficial epithelium. Damage to the oral and vaginal mucosa is mediated by Candidalysin, 334 
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a secreted dual function amphipathic peptide toxin encoded by the extent of cellular 335 
elongation gene (ECE1) [85, 86]. Candidalysin adopts an alpha helical conformation in 336 
solution and intercalates into the plasma membrane of epithelial cells, where it forms 337 
heterogeneous and transient lesions that destabilise membrane structure, causing calcium 338 
influx and release of intracellular contents (Figure 1B). Importantly, a C. albicans ece1∆/∆ 339 
null mutant and a mutant that does not express the Candidalysin-encoding region of ECE1 340 
(ece1∆/∆+ECE1∆184-279), form hyphae, adhere to and invade epithelial cells normally, but do 341 
not cause damage or the secretion of pro-inflammatory cytokines. Moreover, both mutants 342 
are attenuated in a murine model of OPC and a Zebrafish swim bladder model of mucosal 343 
infection [85].  344 
Epithelial recognition of Candidalysin triggers mucosal immunity predominantly 345 
through MAPK signalling, activating the p38 and ERK1/2 pathways that in turn activate the 346 
AP-1 transcription factor c-Fos and MAPK phosphatase 1 (MKP1) respectively, alerting the 347 
host to the transition from colonising yeast to invasive, toxin-producing hyphae (Figure 1C). 348 
Low concentrations of Candidalysin (<15 µM) trigger the release of pro-inflammatory 349 
cytokines but do not cause epithelial damage, whereas higher concentrations (70 µM) of 350 
toxin induce pro-inflammatory responses and cause extensive damage, demonstrating that 351 
Candidalysin has dual functionality in a concentration-dependent manner. 352 
Candidalysin-induced activation of epithelial cells culminates in the release of 353 
cytokines including granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-354 
colony stimulating factor (GM-CSF), IL-1α, IL-1β and IL-6 (Figure 1D). C. albicans ECE1 and 355 
Candidalysin mutants induce significantly lower levels of neutrophils to the site of infection 356 
in vivo when compared to wild type controls [85, 86]. 357 
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A host receptor for Candidalysin-induced signalling has yet to be identified; however, 358 
epithelial activation is not mediated through classical PRRs such as Toll-like receptors or C-359 
type lectin receptors [87]. Intriguingly, Candidalysin can permeabilise synthetic lipid bilayers 360 
that do not contain an endogenous receptor [85], suggesting that the toxin may damage 361 
epithelial cells and activate innate immune responses through distinct mechanisms. 362 
A model of mucosal infection has been proposed [85] in which the hyphae of C. 363 
albicans invade the epithelial surface, creating an invasion "pocket" [75] into which 364 
Candidalysin is secreted. During the initial stages of infection, the concentration of 365 
Candidalysin is insufficient to cause appreciable plasma membrane damage, but is 366 
nevertheless recognised by the epithelial cells of the host mucosa, stimulating an innate 367 
immune response. As infection progresses however, the concentration of Candidalysin 368 
within the invasion pocket increases to damage-inducing levels, causing membrane lesions 369 
that facilitate infection. 370 
Vulvovaginal candidasis (VVC) is a disease of immune competent women. 371 
Approximately 75% of women will experience at least one episode of VVC in their lifetime 372 
[88], while almost 9% will suffer from recurrent infection [89]. Symptomatic VVC is 373 
characterised by itching, burning, and pain at the vulvovaginal mucosa, often accompanied 374 
by odorless vaginal discharge [90]. In contrast to the oral epithelium, recruitment of 375 
neutrophils to the site of infection during VVC does not result in fungal clearance but rather, 376 
causes an acute exacerbation of symptoms [91]. 377 
Similar to TR146 oral epithelial cells, treatment of A431 vaginal cells with 378 
Candidalysin causes damage, c-Fos/p-MKP1 signalling and cytokine secretion [86]. Notably, 379 
fungal burdens remain equivalent in mice that receive an intravaginal challenge of wild type 380 
C. albicans or strains unable to express and secrete Candidalysin. However, a significant 381 
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decrease in neutrophil recruitment, damage, and pro-inflammatory cytokine expression was 382 
observed in response to strains unable to produce the toxin, identifying Candidalysin as the 383 
driver of immune pathology in the vaginal environment [86]. Thus, Candidalysin plays a 384 
crucial role in the activation of innate defences against C. albicans hyphae at disparate 385 
mucosal sites in the body. 386 
The pathogenicity of natural C. albicans isolates is perhaps, unsurprisingly, correlated 387 
with the degree of epithelial damage caused, and release of the damage-associated cytokine 388 
IL-1α. Highly variable murine oral responses were observed from several isolates of C. 389 
albicans, including differences in neutrophil recruitment and the robustness of 390 
inflammatory responses [92]. Notably, from a panel of hypha-associated genes tested (ALS3, 391 
SAP4, SAP5, SAP6, HWP1 and ECE1), only significant differences in ECE1 expression 392 
(Candidalysin) was observed between isolates. However, ECE1 expression did not always 393 
correlate with a strains’ ability to damage epithelial cells [92], but this could be due to 394 
differences in adhesion and hypha formation in the individual strains tested and by the 395 
utilisation of a single ECE1 primer set to assess ECE1 gene expression in all strains.  396 
 397 
5. Antimicrobial peptides, alarmins and cytokine responses 398 
A multitude of host factors are known to be rapidly induced in response to C. 399 
albicans infection, including antimicrobial peptides (AMPs), which are among the first 400 
molecules to be released from the mucosal surface. The cathelicidins are a family of broad-401 
spectrum AMPs that are expressed by a variety of epithelial and immune cells. Human 402 
cathelicidin (LL-37) and its murine equivalent (mCRAMP), are induced in response to C. 403 
albicans where they bind to the cell wall of the fungus, resulting in permeabilisation of the 404 
fungal plasma membrane [93]. Following secretion, LL-37 can be further processed into 405 
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shorter peptide fragments (designated RK-31 or KS-30) capable of killing C. albicans with 406 
equal or greater efficacy when compared to full-length LL-37 [94]. However, cathelicidin 407 
does not confer systemic or subcutaneous protection against C. albicans [93]. 408 
Lactoferrin (Lf) also possesses anti-fungal activity and, like LL-37, can be cleaved into 409 
distinct peptides to enhance functionality. Full-length Lf, together with two Lf-derived 410 
peptides (lactoferricin and lactoferrampin), exert candidacidal activity through mechanisms 411 
that involve disruption of the fungal plasma membrane [95-99]. Full-length Lf also induces 412 
apoptosis-like processes within the fungus [100] and sequestration of iron to induce 413 
fungistasis [101].  414 
In contrast to Lf, the cationic salivary protein histatin 5 does not lyse C. albicans 415 
directly, but binds to β-glucans and cell wall proteins including Ssa1p and Ssa2p [102-105].  416 
Once histatin 5 is bound to the C. albicans cell wall, it is transported into the fungus by two 417 
key polyamine transporters (Dur3p and Dur31p) [106, 107], where it exerts fungicidal 418 
activity by disrupting osmotic homeostasis and cell cycle control [102, 108]. 419 
The defensins are a family of cysteine-rich AMPs that exhibit anti-microbial activity 420 
against a wide range of organisms. Several members of the defensin family possess potent 421 
anti-C. albicans activity, including β-defensin 2 and 3 which kill C. albicans through a poorly 422 
defined mechanism that does not involve membrane disruption [109], as well as α-defensin 423 
6 which blocks adhesion of C. albicans to intestinal epithelial cells [110]. The importance of 424 
defensins against C. albicans in vivo is demonstrated by the observation that mice lacking β-425 
defensin 3 are highly susceptible to OPC [111]. 426 
Vitamin D is receiving increasing attention as a potent anti-microbial molecule 427 
involved in pro-inflammatory responses and cytokine regulation [112, 113] that can 428 
counteract pathogen-induced transcriptional changes in host monocytes [114]. Vitamin D3 429 
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exhibits direct anti-C. albicans activity [115], and although the precise mechanism(s) of 430 
action in vivo remain to be determined, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the 431 
hormonal form of Vitamin D, induces potent upregulation of LL-37 in tongue and lung 432 
epithelial cells, monocytes and neutrophils [116, 117]. 433 
Alarmins are endogenous intracellular proteins that are released from host cells 434 
following severe trauma and tissue damage. The S100A8 and S100A9 alarmins are released 435 
from the oral and vaginal mucosa in response to C. albicans infection and contribute to (but 436 
are not essential for), recruitment of neutrophils that function to resolve the symptoms of 437 
infection in the oral, but not vaginal lumen in a strain specific manner [86, 92, 111, 118, 438 
119]. 439 
In addition to AMPs and alarmins, numerous cytokines play a crucial role in the 440 
induction and regulation of innate immune defence against C. albicans. Signalling mediated 441 
through IL-1 and its related cytokines is critical for the induction of effective anti-C. albicans 442 
immunity. Absence of the IL-1 receptor significantly impairs expression of the neutrophil 443 
recruiting molecules CXCL1, CXCL2, CXCL5 and G-CSF and subsequent neutrophil migration 444 
[120]. Furthermore, IL-1 receptor deficient mice (Il1r1-/-) have significantly higher fungal 445 
burdens in the oral cavity at 3, 7, 14 and 21 days post-infection when compared to wild type 446 
controls [121]. 447 
IL-17 has emerged as one of the most important cytokines in mucosal anti-fungal 448 
immunity, with manifold functionality. Produced by a variety of lymphoid-derived cells (both 449 
innate and adaptive) IL-17 has a dramatic impact on innate immunity. While there are 450 
several isoforms of IL-17, each with distinct biological functions, it is IL-17A and IL-17F which 451 
play key roles in antifungal immunity. Although it has been suggested that neutrophils may 452 
produce IL-17, this does not appear to be the case during OPC [122]. However, one of the 453 
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more important roles of the IL-17 cytokines is to activate a neutrophil response. This 454 
involves secretion of chemokines that will recruit neutrophils (e.g. CXCL1/2 and CXCL5), as 455 
well as cytokines that activate neutrophils once they have been recruited to the site of 456 
infection (e.g. G-CSF) [123]. 457 
IL-17 is a potent inducer of anti-microbial peptide (AMP) secretion, notably β-458 
defensins 1 and 3 in mice [111, 123], as well as histatins [124, 125]. Thus, given the 459 
importance of these AMPs during Candida infection [111, 126], the multiple roles of IL-17 in 460 
mediating protection against C. albicans are clearly established. IL-17A also affects the 461 
epithelial cells of the GI tract directly, where it regulates expression of occludins required for 462 
epithelial tight junctions and barrier integrity [127, 128]. Collectively, the multiple 463 
functionalities of IL-17 cytokines act to drive and regulate a number of essential and non-464 
redundant host mechanisms required for effective defence against C. albicans infection at 465 
mucosal surfaces. 466 
Collectively, AMPs, alarmins and cytokines exert numerous protective functions at 467 
mucosal surfaces in response to C. albicans infection, and although our understanding of 468 
these complex processes continues to improve, there is much still to learn, particularly with 469 
respect to fungi.  470 
 471 
6. Mucosal inflammasome responses to C. albicans 472 
Inflammasomes are cytosolic multi-protein complexes that play a critical role in 473 
immunity. They are comprised of a PRR (either a nucleotide-binding domain leucine-rich 474 
receptor (NLR), or an Absent In Melanoma-2 (AIM2) receptor), and are activated in response 475 
to innate recognition of exogenous and endogenous PAMPs and danger-associated 476 
molecular patterns (DAMPs). NLRs contain an N-terminal region comprised of either a PYRIN 477 
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or CARD domain, a central nucleotide-binding oligomerisation domain and a C-terminal 478 
leucine-rich repeat sequence [129, 130]. Physical association between a NLR and an adaptor 479 
protein (apoptosis-associated speck-like protein containing a CARD (ASC)), results in the 480 
recruitment and autocatalytic activation of pro-caspase-1, which subsequently cleaves the 481 
inactive cytokine zymogens pro-IL-1β and pro-IL-18 [131], to yield biologically active 482 
molecules. 483 
While numerous inflammasomes exist [132], those most closely associated with 484 
innate defence against C. albicans at mucosal surfaces are the NLRP3 and NLRC4 complexes 485 
[121, 133]. Tissue specific roles have been ascribed to the NLRP3 and NLRC4 486 
inflammasomes; the NLRP3 inflammasome is present in both haematopoietic and stromal 487 
compartments and plays a crucial role in the prevention of fungal dissemination during oral 488 
infection in vivo [121] while the NLRC4 complex is important for mucosal defence [133]. 489 
The production of active IL-1β from the oral mucosa in response to C. albicans is 490 
dependent upon both NLRP3 and NLRC4, and buccal mucosal tissues upregulate NLRP3 and 491 
NLRP4 expression within 72 h during the innate immune response to C. albicans infection 492 
[133]. Moreover, Nlrp3-/- and Nlrc4-/- knockout mice exhibit a significant reduction in the 493 
expression of IL-17A, IL-17F and antimicrobial peptides in the oral cavity, while the fungal 494 
burden of Nlrc4-/- mice is significantly higher during OPC when compared to wild type 495 
controls [133], highlighting the importance of inflammasome complexes, particularly NLRC4, 496 
for oral defence against C. albicans infection in vivo. 497 
 498 
7. Neutrophils in antifungal innate immunity 499 
Many protective innate immune responses at mucosal surfaces are mediated by 500 
myeloid cells, most notably neutrophils and macrophages, which rapidly infiltrate the site of 501 
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infection. Activation of neutrophils and macrophages is triggered by direct recognition of 502 
fungal PAMPs [134], by chemokines and AMPs, by cytokines released from epithelial cells in 503 
response to Candidalysin (e.g.IL-1α/β, G/GM-CSF, IL-8, CCL20, β-defensin-2/3 and S100A8/9) 504 
[85, 87, 123], and by IL-17 released from resident innate Th17 cells or γδ T cells [135]. 505 
Neutrophils and macrophages express a range of PRRs including TLR2, TLR4, DC-SIGN, 506 
Mincle, Dectin-2 and Dectin-3 that recognise C. albicans cell wall mannoproteins, TLR9 that 507 
responds to DNA, and Dectin-1 that interacts with cell wall β-glucans, leading to their full 508 
activation [134, 136-138].  509 
Activation of PRRs by cognate PAMPs triggers the MAPK and NF-κB intracellular 510 
signalling pathways through the activation of MyD88, the inflammasome complex and SYK 511 
[134]. This signalling leads to downstream production of pro-inflammatory cytokines and 512 
antimicrobial factors, phagocytosis and a unique method of cell death termed NETosis [134, 513 
139]. However, the PAMPs described above are not the only factors that stimulate 514 
neutrophil responses. Indeed, the secreted aspartic proteases (Saps) of C. albicans have also 515 
been shown to recruit neutrophils [140]. Furthermore, the production of IL-17 from innate 516 
type 17 cells (Figure 1E) and potentially, γδ T cells, in response to IL-1α/β released from 517 
epithelial cells will also lead to activation of infiltrating neutrophils [135], and a key role for 518 
IL-1 in coordinating responses to OPC has also been identified [120]. 519 
The classical method of neutrophil-mediated killing of C. albicans hyphae is 520 
phagocytosis followed by a lethal oxidative burst. The interaction between Dectin-1 and 521 
insoluble β-glucan leads to the formation of a phagocytic synapse that greatly improves the 522 
phagocytosis of C. albicans yeast and short hyphae [141]. However, hyphae that are too 523 
large to be phagocytosed by neutrophils remain a threat to mucosal tissues. To destroy 524 
these larger filaments, neutrophils can undergo NETosis, forming Neutrophil Extracellular 525 
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Traps (NETs) [142]. NETosis involves the cell “exploding” to release a web of chromatin 526 
coated with granule enzymes, antimicrobial peptides (e.g. calprotectin), and histones [142-527 
144] (Figure 1F). Although both yeast and hypha morphologies of C. albicans trigger NETosis, 528 
the neutrophil response to hyphae is by far the most rapid. 529 
Several C. albicans-associated triggers of NETosis have been identified, including 530 
reactive oxygen species (ROS) [145], fibronectin [146] and β-glucan, either through Dectin-531 
1/SYK signalling [147], or through the complement receptor (CD11b/CD18) [146, 148]. The 532 
mechanisms of NETosis are now beginning to be elucidated, and appear to involve both 533 
autophagy and chromatin de-condensation through the ROS-activated peptidylarginine 534 
deiminase 4 (PAD4) [149, 150]. As well as killing fungi, NETs are also capable of slowing 535 
hyphal growth, potentially through the sequestration of micronutrients (e.g. zinc) [143].  536 
 537 
8. Macrophages in antifungal innate immunity 538 
Although neutrophils are the dominant myeloid cell recruited to the foci of infection, 539 
macrophages also infiltrate and perform similar protective functions, phagocytosing the 540 
fungus after PRR-PAMP interaction [151], albeit with a lower efficiency of killing when 541 
compared to neutrophils.  542 
Intriguingly, C. albicans has been observed to survive within macrophages and even 543 
escape [152]. Often, this escape involves the formation of hyphae that physically pierce 544 
through the membrane of the phagolysosome and rupture the ingesting macrophage [153], 545 
although C. albicans can also escape macrophages in a non-lytic fashion [154] akin to the 546 
vomocytosis process described for Cryptococcus neoformans. Whatever the mechanism of 547 
escape, macrophages play a lesser role during disseminated C. albicans infection in mice 548 
when compared with neutrophils [134, 138].  549 
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Nevertheless, macrophages phagocytose C. albicans and respond through NLR-PAMP 550 
interactions that stimulate inflammasome assembly (resulting in the secretion of biologically 551 
active IL-1β), and yet another unique form of cell death termed pyroptosis [155]. Notably, 552 
the induction of macrophage pyroptosis by C. albicans is both a temporally and 553 
mechanistically distinct means of escape that precedes hypha-mediated exfiltration [156], 554 
and provides an important source of biologically active IL-1β (Figure 1G). 555 
 556 
9. Innate immune memory 557 
Conventional wisdom has it that while adaptive immunity ‘learns’ and has memory, 558 
innate immunity has no memory. However, recent findings have begun to overturn this 559 
paradigm. From the mid 1950’s onwards, numerous reports observed that administration of 560 
the Bacillus Calmette-Guérin (BCG) vaccine conferred improved resistance to other non-561 
related pathogens, including Staphylococcus aureus [157], Salmonella [158] and C. albicans 562 
[159]. Similar observations have been made following infection of mice with an avirulent 563 
strain of C. albicans, which resulted in improved protection against virulent C. albicans and 564 
pathogenic bacteria, through a macrophage-dependent, but T cell-independent mechanism 565 
[160, 161]. Further to these findings is the landmark observation that mice which receive a 566 
sub-lethal infection of C. albicans are protected for up to 2 weeks against a subsequent 567 
lethal re-infection in a monocyte-dependent, but T and B cell independent manner [162].  568 
Intriguingly, macrophages demonstrate marked plasticity in their effector responses 569 
[163]. The importance of macrophage plasticity was made evident by Quintin et al. [162], 570 
who demonstrated that pre-exposure of macrophages to C. albicans (and particularly to cell 571 
wall β-glucan), results in “functional reprogramming” through epigenetic changes to 572 
histones [162, 164]. Further studies have demonstrated that this functional reprogramming 573 
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is driven by a Dectin-1/Raf1/NF-κB signalling circuit [165]. In addition, reprogrammed 574 
monocytes show a metabolic shift in glycolysis, akin to that seen in the Warburg effect 575 
associated with cancer [166]. The net effect of macrophage reprogramming is an increased 576 
production of pro-inflammatory cytokines including TNFα, IL-1β and IL-6. 577 
 578 
10. Innate type 17 cells 579 
The critical role that IL-17, and particularly the specific lymphocytes that produce it 580 
play in innate immunity to C. albicans has recently come to light in a series of landmark 581 
studies [111, 135, 167]. These studies demonstrate that mice with defects in the IL-17 582 
receptor or downstream signalling components are highly susceptible to OPC [111]. Equally, 583 
the genetic basis for many cases of chronic mucocutaneous candidiasis (a condition 584 
characterised by perpetual C. albicans infection of the skin, nails and mucosal surfaces), has 585 
now been identified as a collection of loss-of-function mutations in IL-17 signalling [168-586 
170], and auto-antibodies against IL-17 [171, 172]. 587 
Although IL-17 is produced by Th17 T cells of the classical adaptive immune 588 
response, it is a common mistake to regard IL-17 as a cytokine that functions purely in an 589 
adaptive capacity. Indeed, detailed and extensive research clearly demonstrates that IL-17 is 590 
produced by a broad selection of innate immune cells, including γδ-T cells, natural killer T 591 
cells (NKT), type 3 innate lymphoid cells (ILC3) and TCRβ+ ‘natural’ Th17 cells (nTh17) [173]. 592 
While ILC3s have been suggested to play a major role in protection against OPC [174], 593 
recent research has since indicated that nTh17 and γδ-T cells are the predominant source of 594 
IL-17 as Rag1-/- mice, which produce ILC3 cells but not nTh17 or γδ-T cells, have the same 595 
high susceptibility to OPC as IL-17R-/- mice [167].   596 
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The induction of innate type 17 immunity differs considerably from conventional 597 
adaptive immune responses to C. albicans, which are considered to be activated through 598 
CARD9 signalling [175].  Notably, CARD9 signalling is not required to drive innate type 17 599 
responses [176], and innate type 17 cells are observed to be activated in response to the 600 
secretion of Candidalysin from invading C. albicans hyphae [135]. Indeed, oral infection of 601 
mice with an ece1Δ/Δ C. albicans mutant (does not produce Candidalysin), fail to induce IL-602 
17 production and the characteristic activation of nTh17 cells associated with wild type 603 
responses to OPC. Furthermore, Verma et al. [135] identify a causal link between the 604 
production of IL-1 cytokines and the activation of innate type 17 responses, a finding that 605 
integrates with studies which demonstrate the key role of inflammasomes during murine 606 
OPC [121]. 607 
 608 
11. Conclusions 609 
The tremendous diversity within the microbial populations that comprise the human 610 
microbiota provides a dynamic and ever-present immunological challenge for mucosal 611 
surfaces. Numerous complex and interconnecting mechanisms function during innate 612 
recognition and mucosal responses to C. albicans. The complex molecular events that 613 
transpire to enable disparate mucosal sites to distinguish between commensalism and 614 
pathogenicity are receiving more attention now than ever. Continued research will 615 
undoubtedly increase our understanding of the essential mechanisms of innate immunity 616 
required to control this most common of mucosal pathobionts. 617 
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Figure captions 629 
Figure 1. Innate mucosal immune responses to C. albicans. 630 
A) Adhesion of C. albicans hyphae to the host epithelium is mediated through two key 631 
adhesins; Als3p and Hwp1p. The epithelial PRR EphA2 interacts with β-glucan independently 632 
of fungal morphology. EphA2, E-cadherin and EGFR/HER2 receptor complexes function 633 
during receptor induced endocytosis (RIE), most notably through the interaction of E-634 
cadherin and EGFR/HER2 with the C. albicans invasins Als3p and Ssa1p. B) Candidalysin is 635 
secreted from the hyphae of C. albicans where it inserts into the host epithelial membrane, 636 
damaging the cell through the formation of pores that result in loss of intracellular contents 637 
(i.e. lactate dehydrogenase (LDH)), and influx of calcium. C) Epithelial detection of 638 
Candidalysin activates the MAPK signalling pathway (particularly p38) which activates the 639 
AP-1 transcription factor c-Fos, driving cytokine expression. Pathway activity is fine-tuned 640 
through the action of MKP1 on p38 and JNK. D) In response to C. albicans infection, 641 
epithelial cells secrete antimicrobial peptides (AMPs) and alarmins that combat the invading 642 
fungus, together with cytokines and chemokines that recruit and activate myeloid cells 643 
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including innate type 17 cells, neutrophils and macrophages. E) Following infection with C. 644 
albicans, epithelial cells release IL-1 which activates innate type 17 cellular responses, 645 
leading to the secretion of IL-17. F) Neutrophils interact with C. albicans through PRRs (TLRs, 646 
CLRs and NLRs), then phagocytose and destroy yeast and short hyphae. Cytokine signals 647 
stimulate release of TNF-α from neutrophils which upregulates TLR4 expression on epithelial 648 
cells, conferring additional protection. Hyphae that are too large to be phagocytosed 649 
stimulate the production of neutrophil extracellular traps (NETs) through a process termed 650 
NETosis. G) C. albicans that is phagocytosed by macrophages may avoid destruction through 651 
the induction of pyroptosis and hyphal growth, allowing the fungus to escape from the 652 
macrophage. Adapted from [177]. 653 
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